title: Reversal of rotenone-induced dysfunction of astrocytic connexin43 by opening mitochondrial ATP-sensitive potassium channels.
abstract: Growing evidence suggests that the astrocytic gap junctions (GJs), mainly formed by connexin 43 (Cx43), play an important role in physiological maintenance and various central nervous system (CNS) pathological conditions. However, little is known about the role of Cx43 in Parkinson's disease (PD). In this article, we report that rotenone, a classic neurotoxin for PD, could inhibit expression of astrocytic Cx43 and gap junction permeability. ATP-sensitive potassium (K(ATP)) channel openers, iptakalim (IPT) and diazoxide (DZ), exerted protective effect on rotenone-induced dysfunction of Cx43 and astrocyte apoptosis, which was reversed by selective mitochondrial K(ATP) (mitoK(ATP)) channel blocker 5-hydroxydecanoate (5-HD). Taken together, our findings reveal that rotenone-induced dysfunction of astrocytic Cx43 may be involved in the pathology of PD. Moreover, opening mitoK(ATP) channels in astrocytes can reverse rotenone-induced dysfunction of astrocytic Cx43 and therefore protect against toxicity of rotenone on astrocytes.
authors.affiliation: Department of Pharmacology, Nanjing Medical University, Jiangsu, People's Republic of China.
authors.forename: Shu
authors.initials: S
authors.lastname: Zhang
authors.forename: Rui
authors.initials: R
authors.lastname: Liang
authors.forename: Fang
authors.initials: F
authors.lastname: Zhou
authors.forename: Xu
authors.initials: X
authors.lastname: Huang
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Ding
authors.forename: Gang
authors.initials: G
authors.lastname: Hu
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000187:drug effects; D001253:Astrocytes / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D002463:Cell Membrane Permeability / Q000187:drug effects; D002478:Cells, Cultured; D018031:Connexin 43 / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D019610:Cytoprotection / Q000187:drug effects; D004353:Drug Evaluation, Preclinical; D017629:Gap Junctions / Q000187:drug effects / Q000378:metabolism; D015640:Ion Channel Gating / Q000187:drug effects*; D015221:Potassium Channels / Q000819:agonists* / Q000378:metabolism*; D011437:Propylamines / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D012402:Rotenone / Q000633:toxicity*; D014475:Uncoupling Agents / Q000633:toxicity
chemical_list: D018031:Connexin 43; C502260:N-(1-methylethyl)-1,1,2-trimethylpropylamine; D015221:Potassium Channels; D011437:Propylamines; D014475:Uncoupling Agents; C117780:mitochondrial K(ATP) channel; D012402:Rotenone
references.citation: Nat Neurosci. 2005 Dec;8(12):1742-51
references.pmid: 16299504
references.citation: Neuropharmacology. 2005 Jun;48(7):984-92
references.pmid: 15857625
references.citation: Brain Res Brain Res Rev. 2000 Apr;32(1):45-56
references.pmid: 10751656
references.citation: Nat Rev Neurosci. 2006 Mar;7(3):194-206
references.pmid: 16495941
references.citation: Biochim Biophys Acta. 2004 Mar 23;1662(1-2):149-58
references.pmid: 15033585
references.citation: Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11613-8
references.pmid: 10500225
references.citation: J Neurosci Res. 2002 Aug 15;69(4):559-66
references.pmid: 12210849
references.citation: Neurosci Lett. 2004 Aug 5;366(1):53-7
references.pmid: 15265589
references.citation: Mol Membr Biol. 2001 Apr-Jun;18(2):117-27
references.pmid: 11463204
references.citation: Apoptosis. 2005 May;10(3):459-69
references.pmid: 15909108
references.citation: Neuroscientist. 2001 Oct;7(5):396-405
references.pmid: 11597099
references.citation: Eur J Pharmacol. 2005 Mar 28;511(2-3):81-7
references.pmid: 15792775
references.citation: Glia. 2006 Nov 15;54(7):758-773
references.pmid: 17006904
references.citation: Neuropsychopharmacology. 2007 Dec;32(12):2570-80
references.pmid: 17356569
references.citation: J Biol Chem. 2001 Sep 7;276(36):33369-74
references.pmid: 11441006
references.citation: Int J Biochem Cell Biol. 2010 May;42(5):762-70
references.pmid: 20093193
references.citation: Nat Rev Neurosci. 2003 Dec;4(12):991-1001
references.pmid: 14682361
references.citation: Neuroscientist. 2003 Feb;9(1):5-9
references.pmid: 12580335
references.citation: Cell Commun Adhes. 2003 Jul-Dec;10(4-6):401-6
references.pmid: 14681048
references.citation: Exp Cell Res. 1987 Feb;168(2):422-30
references.pmid: 2433137
references.citation: Mov Disord. 2008 Mar 15;23(4):474-83
references.pmid: 18044695
references.citation: Neuroscience. 2009 Apr 21;160(1):61-8
references.pmid: 19232380
references.citation: Biochem Biophys Res Commun. 2007 Jan 5;352(1):97-103
references.pmid: 17107662
references.citation: Cell Death Differ. 2007 Jul;14(7):1324-35
references.pmid: 17431421
references.citation: Nat Neurosci. 2006 Jul;9(7):917-24
references.pmid: 16732273
references.citation: Science. 2000 Nov 10;290(5494):1068
references.pmid: 11184997
references.citation: Life Sci. 2006 Mar 20;78(17):1940-4
references.pmid: 16216278
references.citation: Stroke. 2003 Aug;34(8):1987-93
references.pmid: 12843358
references.citation: J Neurochem. 2001 Jun;77(6):1601-10
references.pmid: 11413243
references.citation: Methods Enzymol. 1985;109:341-5
references.pmid: 2985921
references.citation: Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):495-500
references.pmid: 11756680
references.citation: Glia. 2005 Jun;50(4):351-361
references.pmid: 15846800
references.citation: J Neurochem. 2005 Sep;94(6):1570-9
references.pmid: 16000145
references.citation: Mol Cell Neurosci. 2001 Dec;18(6):671-90
references.pmid: 11749042
references.citation: J Physiol. 1999 Jan 15;514 ( Pt 2):327-41
references.pmid: 9852317
references.citation: Curr Probl Cardiol. 2006 Mar;31(3):181-264
references.pmid: 16503249
references.citation: Neuroscience. 2005;133(1):117-35
references.pmid: 15893636
references.citation: Behav Brain Res. 2002 Oct 17;136(1):317-24
references.pmid: 12385818
references.citation: Int J Neuropsychopharmacol. 2006 Feb;9(1):51-61
references.pmid: 15927086
references.citation: J Neurochem. 2008 Aug;106(3):1000-16
references.pmid: 18410504
references.citation: J Neurosci Res. 2005 May 1;80(3):442-9
references.pmid: 15795934
references.citation: Brain Res. 1996 Apr 22;717(1-2):173-8
references.pmid: 8738268
references.citation: Brain Res Brain Res Rev. 2004 Dec;47(1-3):290-303
references.pmid: 15572178
references.citation: J Neurochem. 2006 Nov;99(4):1049-61
references.pmid: 16899068
references.citation: J Neurochem. 2007 Oct;103(2):569-79
references.pmid: 17635669
references.citation: Neuropsychopharmacology. 2006 May;31(5):933-40
references.pmid: 16123757
references.citation: Nat Neurosci. 2000 Dec;3(12):1301-6
references.pmid: 11100151
references.citation: Prog Neurobiol. 2000 Sep;62(1):63-88
references.pmid: 10821982